L-carnitine does not reduce cancer-related fatigue

September 18, 2012
L-carnitine does not reduce cancer-related fatigue
Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical Oncology.

(HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical Oncology.

To determine whether L-carnitine improves fatigue in , Ricardo A. Cruciani, M.D., of the Beth Israel Medical Center in New York City, and colleagues conducted an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled study involving 376 patients with invasive malignancies who received either 2 g/day of L-carnitine oral supplement or matching placebo for four weeks.

The researchers found that fatigue, as measured using the Brief Fatigue Inventory, improved in both treatment arms compared with baseline, but there was no significant between-group difference. In a subgroup analysis, L-carnitine supplementation also did not improve fatigue in those who were carnitine-deficient at baseline. Neither depression nor pain was improved, as measured using the Functional Assessment of Chronic Illness Therapy-Fatigue instrument. The improvement in both arms suggests a large .

"This is the largest clinical trial to date studying the effect of L-carnitine supplementation on patients with invasive and fatigue," the authors write. "In this phase III, randomized, double-blind, placebo-controlled study, we observed that 1 g twice daily of oral L-carnitine supplementation for four weeks does not improve fatigue, depression, or pain in patients with cancer."

Explore further: Iron supplements can reduce fatigue in nonanemic women

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Iron supplements can reduce fatigue in nonanemic women

July 9, 2012
Iron supplementation reduced fatigue by almost 50% in women who are low in iron but not anemic, according to the results of a clinical trial published July 9 in CMAJ (Canadian Medical Association Journal).

Ginseng fights fatigue in cancer patients, study finds

June 4, 2012
High doses of the herb American ginseng (Panax quinquefolius) over two months reduced cancer-related fatigue in patients more effectively than a placebo, a Mayo Clinic-led study found. Sixty percent of patients studied had ...

Web-Based program helps manage cancer-Related fatigue

March 13, 2012
(HealthDay) -- An Internet-based educational program helps disease-free cancer survivors better manage their cancer-related fatigue (CRF), according to research published online March 12 in the Journal of Clinical Oncology.

Adding ketamine to opioids doesn't reduce cancer pain

September 11, 2012
(HealthDay)—Using subcutaneously administered ketamine in a dose-escalating regimen as an adjunct to opioids and standard co-analgesics does not have any clinical benefit in relieving cancer pain, but it is associated with ...

Supplement burns muscle fat, improves exercise performance

June 30, 2011
A new study has shown for the first time that taking a particular food supplement increases muscle carnitine content and reduces muscle carbohydrate use, while increasing fat used for energy production during exercise.

Recommended for you

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

Bolstering fat cells offers potential new leukemia treatment

October 16, 2017
Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients, according to a new study from McMaster University.

Study reveals complex biology, gender differences, in kidney cancer

October 13, 2017
A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.